Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 11
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.81%
|
$7,125
$19.14 P/Share
|
|
May 11
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,563
-4.49%
|
$29,697
$19.14 P/Share
|
|
Apr 16
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.03%
|
$260,000
$26.23 P/Share
|
|
Apr 16
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.79%
|
$160,000
$16.23 P/Share
|
|
Mar 17
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
17,727
-4.38%
|
$478,629
$27.46 P/Share
|
|
Mar 17
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.62%
|
$160,000
$16.23 P/Share
|
|
Feb 18
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,250
-3.46%
|
$35,000
$28.67 P/Share
|
|
Feb 17
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,250
-3.35%
|
$33,750
$27.35 P/Share
|
|
Feb 08
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.98%
|
$149,203
$31.58 P/Share
|
|
Feb 08
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.53%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
2,250
-5.63%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
2,250
-5.68%
|
$69,750
$31.58 P/Share
|
|
Feb 08
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.86%
|
$34,875
$31.58 P/Share
|
|
Feb 08
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.37%
|
$34,875
$31.58 P/Share
|
|
Feb 05
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.89%
|
$149,203
$31.41 P/Share
|
|
Feb 05
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.13%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
2,250
-5.33%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
2,250
-5.38%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.83%
|
$34,875
$31.41 P/Share
|
|
Feb 05
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.32%
|
$34,875
$31.41 P/Share
|
|
Feb 04
2021
|
Steve Aselage Director |
BUY
Bona fide gift
|
Indirect |
25,000
+50.0%
|
-
|
|
Feb 04
2021
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
25,000
-13.17%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+9.51%
|
-
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.92%
|
-
|
|
Feb 03
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.63%
|
-
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+6.81%
|
-
|
|
Feb 03
2021
|
William E. Rote Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.71%
|
-
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+8.48%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,406
-1.59%
|
$67,368
$28.91 P/Share
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-5.17%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
3,175
-3.94%
|
$88,900
$28.91 P/Share
|
|
Feb 03
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,625
-4.51%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.99%
|
$50,764
$28.91 P/Share
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.98%
|
$15,764
$28.91 P/Share
|
|
Feb 02
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.97%
|
$16,890
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
25,000
-11.28%
|
$750,000
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.14%
|
$250,000
$10.09 P/Share
|
|
Feb 02
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-4.69%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,734
-2.76%
|
$262,020
$30.18 P/Share
|
|
Feb 02
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
3,175
-3.65%
|
$95,250
$30.75 P/Share
|
|
Feb 02
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,625
-4.14%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.92%
|
$54,390
$30.75 P/Share
|
|
Jan 31
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.24%
|
-
|
|
Jan 31
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.57%
|
-
|
|
Jan 31
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.19%
|
-
|
|
Jan 31
2021
|
William E. Rote Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.08%
|
-
|
|
Jan 31
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+9.48%
|
-
|
|
Jan 21
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
57,260
+28.3%
|
-
|
|
Jan 21
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+30.32%
|
-
|
|
Jan 21
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+20.49%
|
-
|